Journal of cancer science and clinical therapeutics最新文献_第9页

Aspects on the International Commission on Non-Ionizing Radiation Protection (ICNIRP) 2020 Guidelines on Radiofrequency Radiation 国际非电离辐射防护委员会(ICNIRP) 2020年《射频辐射指南》的各个方面

Journal of cancer science and clinical therapeutics Pub Date : 2021-01-01 DOI: 10.26502/JCSCT.5079117

L. Hardell, Mona Nilsson, T. Koppel, M. Carlberg

引用次数: 15

Survival Benefits Associated with Surgery in Patients with Metastatic Breast Cancer by Breast Cancer Subtype 乳腺癌亚型转移性乳腺癌患者手术相关的生存获益

Journal of cancer science and clinical therapeutics Pub Date : 2021-01-01 DOI: 10.26502/jcsct.5079127

H.S. Han, T. -, Jyh‐cherng Yu, M. Golshan, Huan-Ming Hsu, C. Chu, Z. Hong, C. Fu, Y. Chou, M. Dai, G. Liao

{"title":"Survival Benefits Associated with Surgery in Patients with Metastatic Breast Cancer by Breast Cancer Subtype","authors":"H.S. Han, T. -, Jyh‐cherng Yu, M. Golshan, Huan-Ming Hsu, C. Chu, Z. Hong, C. Fu, Y. Chou, M. Dai, G. Liao","doi":"10.26502/jcsct.5079127","DOIUrl":"https://doi.org/10.26502/jcsct.5079127","url":null,"abstract":"Background: Two randomized trials have examined the role of local therapy on survival in the stage IV setting of breast cancer, largely suggesting no benefit. However, the effect of surgery for stage IV disease amongst various breast cancer subtypes is not well characterized. In this study, we aimed to evaluate the survival benefit of surgery in patients with stage IV breast cancer based on molecular subtype. J Cancer Sci Clin Ther 2021; 5 (3): 414-425 DOI: 10.26502/jcsct.5079127 Journal of Cancer Science and Clinical Therapeutics 415 Methods: Using an institutional database, we extracted 255 women with a clinicopathologic confirmed diagnosis of stage IV breast cancer who were treated between January 2006 and October 2016. We collected patient data including age, clinical T stage, clinical N stage, histological grade, estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and the use of radiotherapy, chemotherapy, targeted therapy and/or endocrine therapy. Correlates of overall survival (OS) and breast cancer-specific survival (BCSS) in the surgical and non-surgical groups were identified on multivariate analysis. Results: The median overall survival in the surgical group and the non-surgical group was 30.3 months and 20.7 months, respectively. There were significant differences between the two groups according to subtype in the distribution of OS and BCSS (P <0.001). On multivariate analysis for the OS and BCSS, using non-surgical group as a reference, there were significant improvement for the luminal B subtype (P=0.010). Conclusion: This study suggest that surgery of the primary breast tumor may have a positive impact on OS and BCSS in patients with stage IV breast cancer, especially in the luminal B subtype.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69348050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Analytical Anisotropic Algorithm Calculation in Total Body Irradiation: A Comparison with Monte Carlo Calculation and Dosimetry 全身照射的解析各向异性算法计算:与蒙特卡罗计算和剂量法的比较

Journal of cancer science and clinical therapeutics Pub Date : 2021-01-01 DOI: 10.26502/jcsct.5079136

Saikkonen A, Ojala J, Keyrilainen J

{"title":"Analytical Anisotropic Algorithm Calculation in Total Body Irradiation: A Comparison with Monte Carlo Calculation and Dosimetry","authors":"Saikkonen A, Ojala J, Keyrilainen J","doi":"10.26502/jcsct.5079136","DOIUrl":"https://doi.org/10.26502/jcsct.5079136","url":null,"abstract":"Purpose: This study aimed to investigate the feasibility and accuracy of an analytical anisotropic algorithm calculation of the Varian Eclipse treatment planning system in the TBI treatment planning at an extended source-to-surface distance of 400 cm. Materials and Methods: The TBI treatment was planned with the Varian Eclipse TPS using the AAA for the dose calculation. Monte Carlo calculations were performed using the EGSnrc code package. Percentage depth dose curves, central axis dose profiles and absolute doses of the 6 MV photon beams from the Varian TrueBeam linear accelerator were measured at an extended SSD of 400 cm in water, solid water and anthropomorphic phantoms. Results: Calculated and measured PDD curves were in good agreement at the depths of 30.0 cm or less. Calculated J Cancer Sci Clin Ther 2021; 5 (4): 532-547 DOI: 10.26502/jcsct.5079136 Journal of Cancer Science and Clinical Therapeutics 533 and measured central axis dose profiles were clinically acceptable, observing the largest uncertainties close the field edges. Absolute dose measurements in water phantoms showed that the MC and AAA calculations overestimated doses by up to 2.2 % and 1.8 %, respectively. In the anthropomorphic phantom, the difference between measured and calculated mean doses in the whole body volume was 1.0 % and 6.2 % for MC and AAA, respectively. In the AAA calculation, the largest observed difference was 8.3 % in the head. Conclusions: The Eclipse’s AAA calculation can be safely used for the TBI treatment planning at the extended SSD of 400 cm. However, in order to achieve a higher level of accuracy in the TBI planning, one must carefully validate the TPS at extended SSDs.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69348163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Profile of Tissue Selenium Concentration In A Cohort Of Nigerian Men With Prostate Cancer 尼日利亚前列腺癌男性队列组织硒浓度分析

Journal of cancer science and clinical therapeutics Pub Date : 2021-01-01 DOI: 10.26502/jcsct.5079140

Igbokwe Mc, Badmus Ta, Salako Aa, Obiajunwa Ei, O. O., Igbokwe Ca, D. ra

引用次数: 0

Identifying the Mutational Profile of ABCB5 Upregulation in Colorectal Cancer: A Comprehensive Database Analysis 确定结直肠癌中ABCB5上调的突变谱:一个全面的数据库分析

Journal of cancer science and clinical therapeutics Pub Date : 2021-01-01 DOI: 10.26502/jcsct.5079123

R. Sexton, K. Danasekaran, H. Khan, H. Uddin, M. N. Al-Hallak, Y. Landesman, T. Kashyap, Yiwei Li, A. Aboukameel, A. Azmi

{"title":"Identifying the Mutational Profile of ABCB5 Upregulation in Colorectal Cancer: A Comprehensive Database Analysis","authors":"R. Sexton, K. Danasekaran, H. Khan, H. Uddin, M. N. Al-Hallak, Y. Landesman, T. Kashyap, Yiwei Li, A. Aboukameel, A. Azmi","doi":"10.26502/jcsct.5079123","DOIUrl":"https://doi.org/10.26502/jcsct.5079123","url":null,"abstract":"Colorectal cancer (CRC) is a leading cause of cancer related deaths worldwide and the third leading cause of cancer related deaths in the United States with a 5-year survival rate of 63%. Depending on the stage of disease, there are differing rates of overall survival: Stage I (90%) vs. Stage IV (14%). There is a clear discrepancy between early and late stage disease due to a variety of factors including acquired genetic and tumor mutations and lack of initial symptoms leading to late stage detection. It is clear that further understanding into the mechanisms of CRC need to be explored in depth to improve overall survival rates. ATP binding cassette subfamily B member 5 (ABCB5) has been found to be pathogenic in a variety of diseases including melanoma and colorectal cancer but there has been few studies looking at the cellular consequences of ABCB5 upregulation in CRC cells. Using publicly accessible databases, we explored ABCB5 positivity in CRC cells and found novel interactions with 64 differentially expressed genes involved in cellular processes like modulation of inflammation, (XCL1, TNFSF4), enhanced cell signaling via interaction with serine protease inhibitors (SERPINB4, WFDC6) and downregulation of anti-apoptotic proteins (SPIN2A). Although ABCB5 upregulation is not currently targetable with pre-clinical compounds, our analysis revealed the genetic effects induced by ABCB5 upregulation are targetable, including evidence of sensitivity to the XPO1 inhibitor XPOVIO (selinexor). It is clear further pre-clinical investigation is needed to validate these findings.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69367550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Experience using Osimertinib in Patients with Recurrent Malignant Gliomas Containing EGFR Alterations. 奥西美替尼治疗EGFR改变的复发性恶性胶质瘤的临床经验。

Journal of cancer science and clinical therapeutics Pub Date : 2021-01-01 Epub Date: 2021-04-29 DOI: 10.26502/jcsct.5079114

Marin Abousaud, Naqeeb M Faroqui, Glenn Lesser, Roy E Strowd, Shakti H Ramkissoon, Madan Kwatra, Kristin S Houston, Fang-Chi Hsu, Annette Carter, Robin Petro, Alisha T DeTroye

{"title":"Clinical Experience using Osimertinib in Patients with Recurrent Malignant Gliomas Containing EGFR Alterations.","authors":"Marin Abousaud, Naqeeb M Faroqui, Glenn Lesser, Roy E Strowd, Shakti H Ramkissoon, Madan Kwatra, Kristin S Houston, Fang-Chi Hsu, Annette Carter, Robin Petro, Alisha T DeTroye","doi":"10.26502/jcsct.5079114","DOIUrl":"10.26502/jcsct.5079114","url":null,"abstract":"Background: EGFR alterations are commonly observed in malignant gliomas (MG). Osimertinib, an irreversible EGFR-tyrosine kinase inhibitor, effectively penetrates the blood brain barrier and achieves therapeutic concentrations in brain tissue.Materials and methods: This retrospective chart review identified six patients with recurrent MG and EGFR alterations who received osimertinib.Results: Four patients were assessed for response. One patient had a partial response, two patients achieved stable disease and one was refractory. One patient with an EGFR vIII rearrangement remained on treatment for 236 days and a second patient with an EGFR vIII mutation remained on treatment for 294 days and continued on treatment at the time of analysis. Thrombocytopenia occurred in two patients, one patient developed grade 1 diarrhea and pneumonia, and another patient developed grade 1 mucositis.Conclusion: Osimertinib had a tolerable safety profile in this heavily pretreated brain tumor population. Osimertinib may benefit select patients with recurrent MG containing EGFR alterations.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"5 2","pages":"210-220"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121798/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9174799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epileptogenic Temporal lobe Intrinsic Epidermoid Tumor: A Rare Case Report and Review of the Literature 癫痫致颞叶内生性表皮样瘤1例报告及文献复习

Journal of cancer science and clinical therapeutics Pub Date : 2021-01-01 DOI: 10.26502/jcsct.5079124

Mohammad Sujan Sharif, Tarikul Islam KM, Abdur Rahman, Abu Bakar Siddik, Masum Rahman

引用次数: 0

Development and Management of Massive Subcutaneous Metastases with Unusual Clinical Course from Uterine Leiomyosarcoma 子宫平滑肌肉瘤伴异常病程的大量皮下转移的发展与处理

Journal of cancer science and clinical therapeutics Pub Date : 2021-01-01 DOI: 10.26502/jcsct.5079131

Filippin Dm, Nuvola G, Nannini M, S. M, Cammelli S, De Paolis M, Perrone Am, De Iaco P, De Leo A, A. A., Pan Ma

引用次数: 0

The Role of Radiation Therapy in Recurrent Ovarian Cancer 放射治疗在复发性卵巢癌中的作用

Journal of cancer science and clinical therapeutics Pub Date : 2021-01-01 DOI: 10.26502/jcsct.5079143

Yuichiro Hotta, Tamina Kino, H. Shigeta

{"title":"The Role of Radiation Therapy in Recurrent Ovarian Cancer","authors":"Yuichiro Hotta, Tamina Kino, H. Shigeta","doi":"10.26502/jcsct.5079143","DOIUrl":"https://doi.org/10.26502/jcsct.5079143","url":null,"abstract":"Recent remarkable technological advances in radiation therapy made the way for stereotactic body RT (SBRT), which can be used for oligometastatic tumors anywhere in the body. Oligometastases from gynecological malignancies have been considered as one of the most promising candidate for SBRT. It is suggested that SBRT was associated with high rates of local control, impressive survival, and minimal toxicity in ovarian cancer. It is also suggested that SBRT serves to destroy chemoresistant tumor clones, and help stimulate innate immune response or expose tumor neoantigens, and can be used in women who have had prior radiotherapy. Among the ovarian cancers, clear cell cancer might be a good candidate for radiation therapy because it is less sensitive to standard platinum-based chemotherapy. A patient was reported who had recurrent ovarian clear cell cancer and had been free from disease more than ten years after the discontinuation of proton beam therapy. Proton beam therapy provides superior dose distributions and a dosimetric advantages over photon beam therapy. Therefore, radiation therapy is considered to be an effective and safe option for oligometastatic ovarian cancer patients. Proton beam therapy is a good potential option for chemotherapy-resistant, localized, recurrent ovarian cancer including clear cell cancer. J Cancer Sci Clin Ther 2022; 6 (1): 25-30 DOI: 10.26502/jcsct.5079143 Journal of Cancer Science and Clinical Therapeutics 26","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69348225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stress-Induced Accumulation of HnRNP K into Stress Granules. 应力诱导的HnRNP - K在应力颗粒中的积累

Journal of cancer science and clinical therapeutics Pub Date : 2021-01-01 Epub Date: 2021-10-15 DOI: 10.26502/jcsct.5079129

Jayoung Kim, Austin Yeon, Woong-Ki Kim, Khae-Hawn Kim, Takbum Ohn

引用次数: 0